Wickham Laboratories is pleased to announce the introduction of a new in vitro test method, the Monocyte Activation Test (MAT), for the assessment of pyrogenicity of pharmaceutical products and medical devices.
The MAT is a non-animal alternative to the traditional rabbit pyrogen test and we are pleased to have introduced it as part of our commitment to the reduction, refinement and replacement of animal testing.
We have successfully verified the Merck PyroDetect System for the purpose of the pyrogenicity assessment via MAT according to European Pharmacopoeia 2.6.30. The MAT can detect pyrogenic contamination such as
- Gram-positive (non-endotoxin)
- Gram-negative (endotoxin)
- other biological (virus, fungi)
Following the European Pharmacopoeia, any new product or device submitted for the MAT testing will be subjected to preparatory testing (product specific validation). Our experienced scientists will establish the suitability of the MAT method for each product, work on the development of an appropriate method and conduct a GMP product specific validation.